Clearbridge Investments LLC Has $102.79 Million Holdings in TG Therapeutics, Inc. $TGTX

Clearbridge Investments LLC decreased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 25.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,448,033 shares of the biopharmaceutical company’s stock after selling 1,196,442 shares during the period. Clearbridge Investments LLC’s holdings in TG Therapeutics were worth $102,786,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in TG Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock worth $472,220,000 after acquiring an additional 319,703 shares during the last quarter. State Street Corp lifted its position in TG Therapeutics by 2.5% during the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock worth $274,180,000 after acquiring an additional 184,339 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock worth $61,144,000 after acquiring an additional 531,759 shares during the last quarter. Congress Asset Management Co. acquired a new position in TG Therapeutics during the 4th quarter worth $57,307,000. Finally, Invesco Ltd. lifted its position in TG Therapeutics by 12.8% during the 3rd quarter. Invesco Ltd. now owns 1,094,334 shares of the biopharmaceutical company’s stock worth $39,533,000 after acquiring an additional 124,429 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $40.95 on Tuesday. The firm’s 50-day moving average is $37.23 and its 200-day moving average is $32.68. TG Therapeutics, Inc. has a 52-week low of $25.28 and a 52-week high of $44.65. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The company has a market cap of $6.27 billion, a price-to-earnings ratio of 14.32 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was up 69.5% compared to the same quarter last year. Equities research analysts anticipate that TG Therapeutics, Inc. will post 1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of TG Therapeutics in a research report on Wednesday, May 27th. Finally, Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $52.50.

About TG Therapeutics

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.